CompletedNot Applicable

Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease

United States134 participantsStarted 2013-01

Plain-language summary

The purpose of this study is to prospectively collect data on doses of Erythropoietic Stimulating Agents (ESA) and Intravenous Iron, and the markers of erythropoietic activity and iron status. These data will be used to derive mathematical models which will subsequently guide dosing of both agents, such that a desired therapeutic outcome is achieved in every patient, while minimizing patient exposure to both agents.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * receiving or expected to receive ESA Exclusion Criteria: * life expectancy less than 12 months * frequent (once or more per month w/in last 6 months) uncontrolled blood loss * frequent (once or more per month w/in last 6 months) hospitalization * frequent (once or more per month w/in last 6 months) access complications

What they're measuring

Hemoglobin Concentration (g/dL)

Timeframe: 52 weeks

Trial details

NCT IDNCT01719146

SponsorUniversity of Louisville

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-06-05

View on ClinicalTrials.gov More Anemia of End Stage Renal Disease trials